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A B S T R A C T
Background
This is an update of a previous Cochrane review published in Issue 1, 2010 and updated in Issue 9, 2015. The role of lymphadenectomy
in surgical management of endometrial cancer remains controversial. Lymph node metastases can be found in approximately 10%
of women who before surgery are thought to have cancer confined to the womb. Removal of all pelvic and para-aortic lymph nodes
(lymphadenectomy) at initial surgery has been widely advocated, and pelvic and para-aortic lymphadenectomy remains part of the
FIGO (International Federation of Gynaecology and Obstetrics) staging system for endometrial cancer. This recommendation is based
on data from studies that suggested improvement in survival following pelvic and para-aortic lymphadenectomy. However, these studies
were not randomised controlled trials (RCTs), and treatment of pelvic lymph nodes may not confer a direct therapeutic benefit, other
than allocating women to poorer prognosis groups. Furthermore, the Cochrane review and meta-analysis of RCTs of routine adjuvant
radiotherapy to treat possible lymphnodemetastases inwomenwith early-stage endometrial cancer foundno survival advantage. Surgical
removal of pelvic and para-aortic lymph nodes has serious potential short-term and long-term sequelae. Therefore, it is important to
investigate the clinical value of this treatment.
Objectives
To evaluate the effectiveness and safety of lymphadenectomy for the management of endometrial cancer.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and Embase to June 2009 for the original
review, updated the search to June 2015 for the last updated version and further extended the search to March 2017 for this version of
the review. We also searched registers of clinical trials, abstracts of scientific meetings, and reference lists of included studies, and we
contacted experts in the field.
Selection criteria
RCTs and quasi-RCTs that compared lymphadenectomy versus no lymphadenectomy in adult women diagnosed with endometrial
cancer.
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Data collection and analysis
Two review authors independently extracted data and assessed risk of bias. Hazard ratios (HRs) for overall and progression-free survival
and risk ratios (RRs) comparing adverse events in women who received lymphadenectomy versus those with no lymphadenectomy
were pooled in random-effects meta-analyses. We assessed the quality of the evidence using the GRADE (Grades of Recommendation,
Assessment, Development and Evaluation) approach.
Main results
978 unique references were identified via the search strategy. All but 50 were excluded by title and abstract screening. Three RCTs
met the inclusion criteria; for one small RCT, data were insufficient for inclusion in the meta-analysis. The two RCTs included in the
analysis randomly assigned 1945 women, reported HRs for survival adjusted for prognostic factors and based on 1851 women and
had an overall low risk of bias, as they satisfied four of the assessment criteria. The third study had an overall unclear risk of bias, as
information provided was not adequate concerning random sequence generation, allocation concealment, blinding, or completeness
of outcome reporting.
Results of the meta-analysis remained unchanged from the previous versions of this review and indicated no differences in overall and
recurrence-free survival between women who underwent lymphadenectomy and those who did not undergo lymphadenectomy (pooled
hazard ratio (HR) 1.07, 95% confidence interval (CI) 0.81 to 1.43; HR 1.23, 95% CI 0.96 to 1.58 for overall and recurrence-free
survival, respectively) (1851 participants, two studies; moderate-quality evidence).
We found no difference in risk of direct surgical morbidity between women who underwent lymphadenectomy and those who did
not undergo lymphadenectomy. However, women who underwent lymphadenectomy had a significantly higher risk of surgery-related
systemic morbidity and lymphoedema/lymphocyst formation than those who did not undergo lymphadenectomy (RR 3.72, 95% CI
1.04 to 13.27; RR 8.39, 95%CI 4.06 to 17.33 for risk of surgery-related systemic morbidity and lymphoedema/lymphocyst formation,
respectively) (1922 participants, two studies; high-quality evidence).
Authors’ conclusions
This review found no evidence that lymphadenectomy decreases risk of death or disease recurrence compared with no lymphadenectomy
in women with presumed stage I disease. Evidence on serious adverse events suggests that women who undergo lymphadenectomy
are more likely to experience surgery-related systemic morbidity or lymphoedema/lymphocyst formation. Currently, no RCT evidence
shows the impact of lymphadenectomy in women with higher-stage disease and in those at high risk of disease recurrence.
P L A I N L A N G U A G E S U M M A R Y
The role of removing lymph nodes as part of standard surgery for endometrial cancer
The issue
Cancer of the lining of the womb (endometrial cancer) is now the most common gynaecological cancer among women in western
Europe and North America. Most of these women (75%) have tumours confined to the body of the womb at the time of diagnosis,
and three-quarters of women will survive for 10 years after diagnosis. Lymph node metastases can be found in one in 10 women who
appear to have cancer confined to the womb at the time of diagnosis, and removal of all pelvic and para-aortic lymph nodes has been
advocated, even for women with presumed early-stage cancer. This recommendation is based on non-randomised studies that suggested
improvement in survival following removal of pelvic and para-aortic lymph nodes. However, treatment of pelvic lymph nodes may
not be beneficial, and additional treatment to lymph nodes might not necessarily be better treatment, especially as surgical removal of
lymph nodes has serious potential short-term and long-term harmful effects.
The aim of the review
To evaluate the safety and efficacy of lymphadenectomy in the management of endometrial cancer.
What are the main findings?
We found only three trials that compared lymphadenectomy with no lymphadenectomy among women with endometrial cancer. One
of these trials could not be included in the meta-analysis of this review, as it provided insufficient information about outcomes for
women. When we combined findings from the two remaining trials, which included 1945 women, we found no evidence that women
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who received lymphadenectomy were less likely to die or have a relapse of their cancer. In addition, severe adverse events experienced
as a consequence of lymphadenectomy outnumbered those reported when no lymphadenectomy was performed.
Quality of the evidence
The overall quality of the evidence for lymphadenectomy versus standard surgery was moderate for survival outcomes and adverse
events (other than evidence for presence or absence of lymphoedema or lymphocyst, which was of high quality). The quality of evidence
for quality of life was very low, as this outcome was not reported.
What are the conclusions?
The uncertainty of whether lymphadenectomy or no lymphadenectomy is best in the management of early-stage endometrial cancer
probably reflects the fact that evidence shows no reduction in death or in disease relapse when lymphadenectomy is performed, rather
than lack of evidence. In addition, women undergoing lymphadenectomy experienced more severe adverse events than those who did
not undergo lymphadenectomy.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Lymphadenectomy for the management of endometrial cancer
Patient or population: women with stage I endometrial cancer
Settings: inpat ient or outpat ient
Intervention: lymphadenectomy
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95%CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Lymphadenectomy
Overall survival
Follow-up: median
37 to 49 monthsa
HR 1.07
(0.81 to 1.43)
1851
(2 studies)
⊕⊕⊕©
Moderateb
As a result of the way
HRs are calculated, as-
sumed and correspond-
ing risks were not est i-
mated
Recurrence- free
survival
Follow-up: median
37 to 49 monthsa
HR 1.23
(0.96 to 1.58)
1851
(2 studies)
⊕⊕⊕©
Moderateb
As a result of the way
HRs are calculated, as-
sumed and correspond-
ing risks were not est i-
mated
Direct surgical mor-
bidity
Study population RR 1.93
(0.79 to 4.71)
1922
(2 studies)
⊕⊕⊕©
Moderateb
17 per 1000 33 per 1000
(13 to 80)
Moderate- risk population
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19 per 1000 37 per 1000
(15 to 89)
Surgery- related
systemic morbidity
Study population RR 3.72
(1.04 to 13.27)
1922
(2 studies)
⊕⊕⊕©
Moderateb
3 per 1000 11 per 1000
(3 to 40)
Moderate- risk population
5 per 1000 19 per 1000
(5 to 66)
Lymphoedema or
lymphocyst
Study population RR 8.39
(4.06 to 17.33)
1922
(2 studies)
⊕⊕⊕⊕
High
8 per 1000 67 per 1000
(32 to 139)
Moderate- risk population
11 per 1000 92 per 1000
(45 to 191)
* The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is based on
the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; HR: Hazard rat io; RR: Risk rat io.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
aMedian follow-up was 37 months (interquart ile range (IQR) 24 to 58 months) in the Kitchener trial and 49 months (IQR 27 to
79 months) in the trial of Panici.
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bEstimate is imprecise, as a fair degree of uncertainty can be seen in the pooled est imate, as indicated by a 95% conf idence
interval.
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B A C K G R O U N D
Description of the condition
Endometrial cancer affects the lining of the womb and is the fifth
most common cancer among women worldwide (Ferlay 2012).
The disease occurs predominantly in postmenopausal women
(91% of cases are reported in women over 50 years old) (Parkin
2005). Global incidences vary as a result of differences in risk fac-
tors, with higher risk associated with a ’western’ lifestyle; the age-
standardised incidence is 14.7 per 100,000 women per year in
more developed countries, compared with 5.5 per 100,000 per
year in less developed countries (Ferlay 2012). One of the main
risk factors for endometrial cancer is unopposed oestrogen, which
may come from exogenous (from outside of the body) sources,
such as oestrogen-only hormone replacement therapy (HRT), or
endogenous (from within the body) overproduction, as is seen
with polycystic ovarian syndrome, oestrogen-producing tumours
and excessive adipose tissue in obese women (Park 2010; Renehan
2008).
Most women present with symptoms of abnormal vaginal bleed-
ing. This typically is reported as postmenopausal bleeding, asmost
cases occur in those over the age of 50, although younger women
may presentwith intermenstrual bleeding,menorrhagia (heavy pe-
riods), or a change in bleeding pattern, and in those over 45 years,
changes in menstruation should be investigated (NICE 2007).
Less common symptoms include low pelvic pain and vaginal dis-
charge. Most women (75% to 80%) with postmenopausal bleed-
ing present with early-stage disease (International Federation of
Gynaecology and Obstetrics (FIGO) stage I), in which the disease
is confined to the womb (Shepherd 1989 -Table 1), (Siegel 2015
- Figure 1). It should be noted that FIGO staging was changed in
2009, following publication of the main studies included in this
analysis (Pecorelli 2009 - Table 2). The 2009 staging system will
be used in this review, unless otherwise stated.
Figure 1. Distribution of stage of endometrial cancer at presentation, USA 2004-2010. Adapted from Siegel
2015.
Histologically most endometrial cancers are endometrioid ade-
nocarcinomas. Other histological subtypes tend to have a poorer
prognosis, as they typically are more aggressive (high grade =
G3) and present at a more advanced FIGO stage. These include
adenosquamous, clear cell and serous carcinomas.
Endometrial cancer directly invades surrounding tissues, most
commonly the myometrium and the cervix. Lymphatic spread
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also occurs, primarily to the pelvic lymph nodes, including exter-
nal and common iliac lymph nodes, and then to the para-aortic
lymph nodes. Results of histopathological studies have demon-
strated spread to pelvic and para-aortic lymph nodes in up to 10%
of cases of early-stage disease (Creasman 1987).Metastasis to more
distant organs is typically haematological.
Description of the intervention
Standard treatment for early-stage endometrial cancer consists of
total hysterectomy, bilateral salpingo-oophorectomy (BSO) and
washings. This may be performed via a laparotomy or by a laparo-
scopic approach. For patients with risk factors for spread beyond
the womb, adjuvant radiotherapy (and increasingly chemother-
apy) is administered to reduce the risk of recurrence.
Randomised controlled trials (RCTs) have demonstrated that ad-
juvant radiotherapy does not improve overall survival In early-
stage disease (FIGO stage I without G3 disease or without evi-
dence of invasion into the lymphovascular space), although it does
reduce the number of pelvic recurrences (Kong 2012). Reducing
the number of pelvic recurrences does not affect survival rates,
probably because pelvic recurrences usually can be treated effec-
tively with radiotherapy in women who have not previously re-
ceived pelvic radiotherapy.
Lymphadenectomy can be considered as clearance of all lymph
nodes or sampling of a few lymph nodes from an anatomical area.
Lymphadenectomy is used to drain the site of cancer when cancers
have spread to the lymph nodes, for example, in breast cancer
surgery. Lymphadenectomy often refers to the systematic removal
of all lymph nodes within a defined area, as opposed to lymph
node sampling, which refers to removal of a few representative
lymph nodes or removal of suspiciously enlarged nodes. Use of
sentinel lymph node biopsy in the management of endometrial
carcinoma is a topic of increasing interest, and studies assessing
the diagnostic accuracy of this procedure have yielded promising
results (Ansari 2013; Kang 2011).
How the intervention might work
Knowledge of cancer spread gives prognostic information and
guides the decision toprovide adjuvant treatment in the formof ra-
diotherapy and chemotherapy. Lymphadenectomy can be directly
therapeutic, as surgery removes involved lymph nodes, which may
be the source of pelvic recurrences. However, lymph node involve-
ment is rare if the tumour is of low grade (G1) or is confined to
the inner half of the myometrium (FIGO stage IA). Hence, surgi-
cal staging involving a lymphadenectomy may be recommended
only for women who are at increased risk of pelvic lymph node
involvement (e.g. those with higher-grade tumours identified by
biopsy) (Kim 1993).
Nevertheless, lymphadenectomy is not performed without seri-
ous short-term and long-term morbidity. Many women with en-
dometrial cancer are elderly or obese and have serious comorbidi-
ties, and the increase in operative time required to perform a full
lymphadenectomy may increase risks of surgery and anaesthesia.
Complications associated with lymphadenectomy include dam-
age to blood vessels and nerves during the operation; develop-
ment of a deep vein thrombosis or pulmonary embolus during the
postoperative period; and lymphoedema and/or pelvic lymphocyst
formation. These complications can be severe and disabling, and
lymphoedema and lymphocyst formation may be under-reported
or under-recognised, especially in studies focusing on short-term
outcomes.
Why it is important to do this review
Debate is ongoing regarding lymphadenectomy for the treatment
of endometrial cancer. Lymphadenectomy may not be routinely
performed, and if it is, the extent of lymphadenectomy can range
from taking a few lymph nodes for sampling to performing com-
plete pelvic and para-aortic lymphadenectomy.
The extent of disease, as assessed by preoperative imaging (such as
magnetic resonance imaging (MRI)) and the grade of tumour as
identified through biopsies, may influence the decision whether
to undertake lymphadenectomy. The ongoing MAPPING study
aims to determine whether MRI, diffusion-weighted MRI, fluo-
rodeoxyglucose positron emission tomography (FDGPET)/com-
puted tomography (CT) and fluoro-ethyl-choline PET/CT can
identify lymph node metastasis and facilitate minimally invasive
or non-invasive lymph node staging (ISRCTN84527805). Results
of this study may further influence the decision to perform lym-
phadenectomy.
Evidence fromone retrospective, non-randomised study suggested
that multiple-site lymph node sampling may increase survival over
procedures that do not include lymph node sampling (Kilgore
1995). In this retrospective review of 649 participants with en-
dometrial cancer, women who underwent multiple-site lymph
node sampling had improved five-year survival (extrapolated from
survival curves) compared with women who underwent no pelvic
node sampling (five-year survival ~90% vs ~75%; P = 0.002). Fur-
thermore, one study found that patients who undergo extensive
lymph node sampling may have increased survival as compared
with those who have fewer lymph nodes removed (Chan 2006).
This retrospective analysis of 12,333 participants with endometri-
oid endometrial cancer demonstrated that participants with high-
risk disease (pre-2009 FIGO stage IB, grade 3 or greater) appeared
to have improved five-year survival rates following extensive lymph
node removal (75.3%with one node removed vs 86.8%with 20 or
more nodes removed; P = 0.001). Another large, population-based
study of 9185 women with stage I and 881 women with stage
II endometrial cancer compared outcomes stratified by whether
lymph node sampling had been performed (Trimble 1998). Over-
all investigators reported no significant differences in five-year sur-
vival for women with stage I and II disease who did or did not
undergo lymph node sampling. In contrast, a retrospective study
of 671 women with endometrial cancer demonstrated improve-
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ment in overall survival for those at intermediate or high risk of
disease recurrence among women who had undergone para-aortic
lymphadenectomy in addition to pelvic lymphadenectomy com-
pared with women treated with pelvic lymphadenectomy alone
(hazard ratio (HR) 0.44, 95% confidence interval (CI) 0.30 to
0.64) (Todo 2010).
However, lymphadenectomy, similar to pelvic radiotherapy (Kong
2012), is not beneficial for most women with endometrial cancer,
as most are unlikely to have lymph node involvement. Therefore,
the additional surgery would make no difference to their chance
of cure or need for further treatment and would benefit only a
minority of women to the detriment of the majority, who would
be cured by hysterectomy and BSO alone. The previous version
of this review did not demonstrate that lymphadenectomy im-
proved survival or reduced disease recurrence compared with no
lymphadenectomy in women with presumed stage I disease (May
2010). However, knowledge of lymph node status does provide
prognostic information and may reduce the need for adjuvant ra-
diotherapy in women found to have negative lymph nodes (Look
2004).
As these data demonstrate, clinical controversy surrounds the role
of lymphadenectomy in endometrial cancer. This procedure car-
ries significant long-termmorbidity for a largeminority of patients
and should be performed only if good evidence demonstrating
improvements in survival and quality of life (QOL) supports its
use.
This review aimed to address the value of lymphadenectomy in
endometrial cancer. This included the effects of routine removal
of all pelvic lymph nodes (pelvic lymphadenectomy) and effects
of routine removal of para-aortic lymph nodes. This review also
assessed evidence for the value of removing clinically suspicious
(enlarged) lymph nodes.
O B J E C T I V E S
To evaluate the effectiveness and safety of lymphadenectomy for
the management of endometrial cancer.
M E T H O D S
Criteria for considering studies for this review
Types of studies
• RCTs and quasi-RCTs. We excluded cross-over trials and
cluster-randomised trials.
Types of participants
Adult women diagnosed with endometrial cancer. We excluded
women with other concurrent malignancies.
Types of interventions
We included the following comparisons.
• Pelvic lymphadenectomy versus no lymphadenectomy.
• Pelvic lymphadenectomy versus pelvic lymph node
sampling.
• Pelvic and para-aortic lymphadenectomy versus no
lymphadenectomy.
• Pelvic and para-aortic lymphadenectomy versus pelvic
lymphadenectomy.
• Removal of bulky pelvic lymph nodes versus no removal of
lymph nodes.
Types of outcome measures
Primary outcomes
• Overall survival (OS).
Secondary outcomes
• Progression-free survival (PFS).
• QOL measured by a validated scale.
• Adverse events, for example,
◦ direct surgical morbidity (e.g. injury to bladder, ureter,
vascular, small bowel (or colon); presence and complications of
adhesions; febrile morbidity; intestinal obstruction; haematoma;
local infection);
◦ surgery-related systemic morbidity (chest infection,
thromboembolic events (deep vein thrombosis and pulmonary
embolism), cardiac events (cardiac ischaemia and cardiac failure),
cerebrovascular accident;
◦ recovery: delayed discharge, unscheduled re-
admission;
◦ lymphoedema and lymphocyst formation; and
◦ other side effects not categorised above.
Search methods for identification of studies
Electronic searches
See the Cochrane Gynaecological Cancer Group methods used in
reviews.
We searched the following electronic databases.
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Original review - 2010
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2009, Issue 2).
• MEDLINE - 1966 to June 2009.
• Embase - 1966 to June 2009.
Updated review - 2015
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2015, Issue 5).
• MEDLINE - June 2009 to June 2015.
• Embase - June 2009 to June 2015.
Updated review - 2017
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2017, Issue 3).
• MEDLINE - June 2015 to March 2017.
• Embase - June 2015 to March 2017.
We developed a search strategy based on terms related to the review
topic (for CENTRAL, MEDLINE and EMBASE search strate-
gies, see Appendix 1, Appendix 2, and Appendix 3).
All relevant articles found were identified on PubMed, and, using
the ’related articles’ feature, we carried out a further search for
newly published articles.
Searching other resources
Unpublished and grey literature
We searched metaregister, Physicians Data
Query, www.controlled-trials.com/rct, www.clinicaltrials.gov and
www.cancer.gov/clinicaltrials for ongoing trials. We contacted the
main investigators of relevant ongoing trials, along with the ma-
jor co-operative trials groups active in this area, to ask for further
information..
Handsearching
We handsearched the reference lists of all relevant trials obtained
by this search to look for further trials.
Correspondence
We contacted authors of relevant trials to ask if they knew of
additional data that may or may not have been published.
Language
We sought papers in all languages and carried out translations
when necessary.
Data collection and analysis
Selection of studies
Original review - 2010
We downloaded all titles and abstracts retrieved by electronic
searching to the reference management database Endnote and re-
moved duplicates. At least two review authors (a combination of
KW, JM, and AB) independently examined the remaining refer-
ences. We excluded studies that clearly did not meet the inclusion
criteria and obtained copies of the full text of potentially relevant
references. Two review authors (JM and KW) independently as-
sessed the eligibility of retrieved papers and resolved disagreements
by discussion between them and, if necessary, with a third review
author (AB). We documented reasons for exclusion.
Updated review - 2015
We downloaded all titles and abstracts retrieved by electronic
searching to the reference management databases Endnote and
Mendeley and removed duplicates. At least two review authors (of
KW, JF, and JM) independently examined the remaining refer-
ences. We excluded studies that clearly did not meet the inclusion
criteria and obtained copies of the full text of potentially relevant
references. Two review authors (KW and JF) independently as-
sessed the eligibility of retrieved papers and, when necessary, re-
quested additional information from study authors. These two re-
view authors resolved disagreements by discussion between them
and, if necessary, with a third review author (JM).We documented
reasons for exclusion.
Update review - 2017
We downloaded all titles and abstracts (MEDLINE: June 2015 to
March week 4 2017 - 61 refs; Embase: June 2015 to 2017 week
13 - 135 refs; Central: Issue 3 of 12 2017 - 54 refs) to the RCT
classifier for de-duplication and identification of possible RCTs.
76 unique references were identified and 20 were identified as pos-
sible clinical trials by the classifier. These 76 references were up-
loaded to Covidence and the 20 potential clinical trials screened
independently by two reviewers (JM and JF). There were no dis-
agreements and no additional studies were identified.
Data extraction and management
We extracted data from the included studies as recommended in
Chapter 7 of the Cochrane Handbook for Systematic Reviews of In-
terventions (Higgins 2011). These data consisted of characteristics
of participants (inclusion criteria, age, stage, comorbidity, previous
treatment, number enrolled in each arm), interventions (extent
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of lymphadenectomy, number of lymph nodes removed, use of
radiotherapy or chemotherapy), study quality, duration of follow-
up, outcomes, any variables used to adjust HRs, and deviations
from the protocol. Two review authors (a combination of JM, KW
and JF) independently extracted data. When possible, all data ex-
tracted were those relevant to an intention-to-treat (ITT) analysis.
Review authors resolved differences by discussion or by appeal to
a third review author (JM), if necessary.
Assessment of risk of bias in included studies
We assessed risk of bias in included RCTs by using the Cochrane
’risk of bias’ tool and the criteria specified in Chapter 8 of the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011). This included assessment of:
• sequence generation;
• allocation concealment;
• blinding (assessment of blinding was restricted to blinding
of outcome assessors, as generally it is not possible to blind
participants and personnel to surgical interventions);
• incomplete outcome data;
• selective reporting of outcomes; and
• other possible sources of bias.
Two review authors (KW and JF) independently applied the ’risk
of bias’ tool and resolved differences by discussion or by appeal to
a third review author (JM). We have presented results in the ’risk
of bias’ table, the ’risk of bias’ graph and the ’risk of bias’ summary
section. We interpreted results of meta-analyses in the light of the
’risk of bias’ assessment.
Measures of treatment effect
• For time-to-event data (overall survival, progression-free
survival), we extracted the HR and its variance from trial reports;
if these were not presented, we would have attempted to abstract
the data required to estimate them using Parmar’s methods
(Parmar 1998) (e.g. number of events in each arm and log-rank
P value comparing relevant outcomes in each arm, or relevant
data from Kaplan-Meier survival curves).
• For dichotomous outcomes (adverse events), we extracted
the number of participants in each treatment arm who
experienced the outcome of interest to estimate a risk ratio (RR).
We also extracted the number of participants assessed at endpoint.
Dealing with missing data
We attempted to extract data on outcomes only for participants
who were assessed at endpoint. We did not impute missing out-
come data; if only imputed outcome data were reported, we con-
tacted trial authors to request data on outcomes only among par-
ticipants who were assessed.
Assessment of heterogeneity
We assessed heterogeneity between studies by visually inspecting
forest plots, by estimating the percentage of heterogeneity between
trials that could not be ascribed to sampling variation (Higgins
2003), by conducting a formal statistical test of the significance
of the heterogeneity (Deeks 2001) and, if possible, by performing
subgroup analyses (see below). If we found evidence of substantial
heterogeneity, we investigated and reported possible reasons for
this.
Assessment of reporting biases
We were unable to assess reporting bias, as only three studies met
our inclusion criteria.
Data synthesis
We pooled the findings of two of the three included trials in meta-
analyses.
• For time-to-event data (overall survival and progression-free
survival), we pooled HRs using the generic inverse variance
facility of RevMan 5. We used adjusted HRs, if available;
otherwise we used unadjusted results.
• For dichotomous outcomes (adverse events), we pooled
RRs.
We used random-effects models with inverse variance weighting
for all meta-analyses (DerSimonian 1986).
We have presented the overall quality of the evidence for each
outcome according to the GRADE approach, which takes into
account issues not only related to internal validity (risk of bias,
inconsistency, imprecision, publication bias) but also to external
validity such as directness of results (Langendam 2013). We have
created a ’Summary of findings’ table based on the methods de-
scribed the Cochrane Handbook for Systematic Reviews of In-
terventions (Higgins 2011) and GRADEpro GDT. We used the
GRADE checklist and GRADE Working Group quality of evi-
dence definitions (Meader 2014). We downgraded the evidence
from ’high’ quality by one level for serious (or by two for very
serious) concerns for each limitation.
Subgroup analysis and investigation of heterogeneity
We performed no subgroup analyses, as only three trials met our
inclusion criteria. The two trials included in the meta-analysis
showed no heterogeneity (I2 = 0).
Sensitivity analysis
We performed no sensitivity analyses, as both of the studies in-
cluded in the analysis were at low risk of bias.
11Lymphadenectomy for the management of endometrial cancer (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
’Summary of findings’ table
R E S U L T S
Description of studies
Results of the search
Original review - 2010
The search yielded 349 unique references. Three review authors
independently read the abstracts of these articles and at this stage
excluded articles that obviously did not meet the inclusion crite-
ria. We retrieved 18 articles in full text and translated them into
English, when appropriate; we identified updated versions of rel-
evant studies. Through full-text screening of these 18 studies, we
excluded 11 trials. However, we identified two completed RCTs
that met our inclusion criteria and five references that provided
preliminary results of the two included studies. See Figure 2 for a
study flow diagram.
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Figure 2. Study flow diagram.
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Updated review - 2015
The search yielded 553 additional unique references. At least two
review authors (of KW, JF and JM) independently read the ab-
stracts of these articles and excluded 521 articles that obviously did
not meet the inclusion criteria. We retrieved 32 articles in full and
subjected them to full-text screening. We subsequently excluded
30 of these. One additional RCT met the inclusion criteria, and
one article provided additional data from a previously included
RCT.
Searches of the grey literature revealed no additional relevant stud-
ies.
Therefore, in this updated version of the review, we excluded
41 of the articles reviewed in full text for the reasons given in
the Characteristics of excluded studies table and included nine
articles reporting results from three RCTs, as described in the
Characteristics of included studies table.
Updated review - 2017
The search yielded 76 additional unique references. On screening,
all articles were excluded and no articles were retrieved in full text.
Included studies
Three studies met the inclusion criteria (Fayallah 2011; Kitchener
2009; Panici 2008). One of these was a small RCT of 38 partici-
pants (Fayallah 2011) designed to assess the role of pretreatment
detection of P53 overexpression in the selection of women with
clinical stage I disease for pelvic lymphadenectomy. We excluded
this study from themeta-analysis, as it was not possible to estimate
hazard or risk ratios for the outcomes of interest in this review
using the data provided. We contacted authors of the Fayallah
2011 study via their published contact details to ask for additional
information, but none has been forthcoming. We also contacted
the publishers of the Fayallah 2011 study to ask for further infor-
mation, but we have received no response.
The two remaining included trials (Kitchener 2009; Panici 2008)
randomly assigned 1945 women, of whom 1923 (99%) were as-
sessed at the end of the trial and 1851 (95%) were assessed in
multivariate survival analyses using Cox models.
Kitchener 2009 reported 191 (13.6%) deaths and 173 (12.3%)
disease recurrences; Panici 2008 reported 53 (10.3%) deaths
and 78 (15.1%) disease recurrences; Kitchener 2009 reported 38
(2.7%) instances of direct surgical morbidity, seven (0.5%) cases
of surgery-related systemic morbidity, 12 (0.9%) cases of lympho-
cyst formation and 26 (1.8%) cases of lymphoedema; Panici 2008
reported 13 (2.5%) instances of direct surgical morbidity, eight
(1.6%) cases of surgery-related systemic morbidity and 39 (7.6%)
cases of lymphoedema/lymphocyst formation.
Fayallah 2011 randomly assigned 38 women and reported four
(10.5%) deaths; seven (18.4%) disease recurrences; five (13.2%)
instances of direct surgical morbidity, one (2.6%) case of surgery-
related systemic morbidity and one (2.6%) case of lymphorrhoea.
The Kitchener 2009 trial (ASTEC)
Design
Between 1998 and 2005, 1408womenwith preoperative endome-
trial cancer thought clinically to be confined to the uterus (womb)
(pre-2009 FIGO stage I) from 85 centres in four countries were
randomly assigned preoperatively to standard surgery (n = 704)
(total hysterectomy, bilateral salpingo-oophorectomy and palpa-
tion of para-aortic lymph nodes) or standard surgery plus sys-
tematic pelvic lymphadenectomy (n = 704) (iliac and obturator
lymph nodes). Women with enlarged lymph nodes in the standard
surgery arm could have these removed at the discretion of the sur-
geon. All operations were performed by specialist gynaecological
surgeons with experience in pelvic lymphadenectomy, and the op-
eration was performed by the same surgeon, regardless of to which
arm the participant was randomly assigned. After surgery, women
with early-stage disease at intermediate or high risk of recurrence
were randomly assigned (independent of lymph node status) to
the ASTEC radiotherapy trial, to control for adjuvant treatment.
Participants
Women were well matched between the two arms in terms of clin-
ico-pathological features, although slightly more poor prognosis
histopathological types were assigned to the lymphadenectomy
arm (clear cell 10 (1%) versus 17 (2%); serous 21 (3%) versus 32
(5%)). In the lymphadenectomy arm, 58 (8%) women had no
nodes removed for reasons including anaesthetic concerns, obe-
sity, obvious late-stage disease or participant request. For those in
the lymphadenectomy arm who did undergo lymphadenectomy,
a median of 12 nodes (range one to 59) were removed. Thirty-
five (5%) women in the standard surgery arm underwent lymph
node sampling with removal of a median of two nodes (range one
to 27). Lymph nodes were invaded by cancerous cells in nine par-
ticipants in the standard surgery arm (27% of the 35 women who
had suspicious nodes removed at the time of surgery) and in 54
(9%) of the 686 women in the lymphadenectomy arm who had
lymph nodes removed.
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Interventions
This study pre-dated routine use of laparoscopic surgery, and
most study participants underwent open surgery. Median oper-
ating time was shorter in the standard surgery group: 60 min-
utes (10 to 255) for standard surgery and 90 minutes (10 to 390)
for lymphadenectomy. Median hospital stay was six days (range
two to 120 days) for standard surgery and six days (range two to
106 days) for lymphadenectomy. Women in the lymphadenec-
tomy arm were more likely to have a vertical than a transverse
(Pfannenstiel) abdominal incision (287 (45%) vertical incisions
for standard surgery versus 384 (60%) vertical incisions for lym-
phadenectomy).
One-third of women in each group received adjuvant radiotherapy
(standard surgery 227 (33%); lymphadenectomy 228 (33%)), and
similar numbers received external beam radiotherapy plus vault
brachytherapy (173 (25%) versus 165 (23%)) or brachytherapy
only (54 (8%) versus 63 (9%)).
Median follow-up was 37 months (interquartile range (IQR) 24
to 58 months).
The Panici 2008 trial
Design
Over 9½ years, 514 participants with endometrial cancer clini-
cally confined to the uterus preoperatively (pre-2009 FIGO stage
I) from 31 centres (30 in Italy and 1 in Chile) were randomly as-
signed to undergo pelvic systematic lymphadenectomy (n = 264)
or no lymphadenectomy (n = 250). All eligible women had frozen
section performed on the uterus to confirm the presence of en-
dometrioid or adenosquamous carcinoma and grade of disease,
and to evaluate the depth ofmyometrial invasion.Womenwithout
myometrial invasion (pre-2009 FIGO stage IA) and those with
a well-differentiated tumour and less than 50% myometrial in-
vasion (G1, pre-2009 FIGO stage IB) were excluded. All other
women were randomly assigned intraoperatively to one of the two
trial arms by a block arrangement that balanced treatment assign-
ments at each site. Women randomly assigned to the pelvic lym-
phadenectomy arm had lymphatic tissue removed from the ex-
ternal iliac, superficial and common iliac regions. Dissection was
considered appropriate only if 20 or more lymph nodes were re-
moved for histopathological examination. Para-aortic node sam-
pling or lymphadenectomy was performed at the discretion of the
surgeon. In the no-lymphadenectomy group, no lymphatic tissue
in the retroperitoneal region was removed other than bulky (> 1
cm) lymph nodes detected at gross intraoperative inspection by
palpation of lymph node sites.
Participants
Women were well matched between the two arms in terms of
clinico-pathological features, except for a higher proportion of
pre-2009 FIGO stage IIIC participants in the lymphadenectomy
arm, following examination of lymph node status. All women al-
located to the lymphadenectomy arm underwent lymphadenec-
tomy, with a median of 26 pelvic lymph nodes removed (range 21
to 35). In the no-lymphadenectomy arm, 56 (22%) women had
enlarged lymph nodes and underwent pelvic lymph node sam-
pling or lymphadenectomy: 28 (11%) had more than 10 lymph
nodes removed. Of these 56 women with bulky lymph nodes, only
eight (15% of those who had lymph nodes removed) had positive
lymph nodes on histological examination. Aortic lymphadenec-
tomy was performed in 69 (26%) of the 264 women in the lym-
phadenectomy arm and in five (2%) of the 250 women in the no
lymphadenectomy arm.
Interventions
Median operating time (180 minutes versus 120 minutes, P <
0.001) and hospital in-patient stay (6 days versus 5 days; P value
< 0.001) were greater in the lymphadenectomy arm than in the
no lymphadenectomy arm.
Rates of adjuvant therapy (pelvic external beam, brachytherapy,
chemotherapy, or combination of chemotherapy and radiother-
apy) were similar between the two arms. Most participants re-
ceived no adjuvant therapy (69% in the lymphadenectomy arm
and 65% in the no-lymphadenectomy arm; P = 0.07).
Median follow-up was 49 months (IQR 27 to 79 months).
The Fayallah 2011 trial
Design
Between April 2005 and October 2008, 38 women with preoper-
ative clinical stage I endometrial carcinoma from a single hospi-
tal were preoperatively randomly assigned to extrafascial hysterec-
tomy, bilateral salpingo-oophorectomy with pelvic lymphadenec-
tomy (n=21) (iliac andobturator lymphnodes) or extrafascial hys-
terectomy andbilateral salpingo-oophorectomy alone (n= 17). Be-
fore surgery, immunohistochemistry was carried out on endome-
trial tissue for detection of P53 over-expression. After surgery, the
decision to provide adjuvant radiotherapy was made at the discre-
tion of tumour board meeting members. Women were followed
up every three months with clinical assessment and ultrasound
and underwent MRI every six months.
Participants
No significant difference was noted between the two arms in terms
of age, medical status, surgical stage, histological type, or grade
of tumour. The number of nodes removed from women in either
arm was not reported.
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Interventions
Operating time, route of surgery, and use of adjuvant therapy were
not reported in the trial.
Mean follow-up after treatment was 21.5 months (range six to 40
months).
Outcomes reported
Both the Panici 2008 trial and the Kitchener 2009 trial reported
overall and recurrence-free survival rates and used appropriate sta-
tistical techniques (HRs to correctly allow for censoring). Inves-
tigators adjusted for prognostic factors in the analysis of survival
outcomes in each trial.
The Fayallah 2011 trial reported survival rate and recurrence rate
as percentages based on participants who were known to have died
or were known to experience disease progression. Hazard ratios
and risk ratios were not reported and could not be estimated from
available data. Study authors provided no additional data.
In the trial of Kitchener 2009, investigators adjusted HR for age
(continuous), World Health Organization (WHO) performance
status (0, 1, 2, 3, or 4), weeks between diagnosis and randomisa-
tion (six weeks or longer vs less than six weeks), surgical technique
intended (open vs laparoscopic), type of incision (vertical vs Pfan-
nenstiel vs other transverse), extent of tumour (confined vs spread),
histology (endometrioid/adenocarcinoma vs other), depth of in-
vasion (inner half vs endometrium, outer half vs endometrium),
differentiation (grade 1, 2, or 3) and centre (dummy variables and
centres with fewer than five women were grouped as one new cen-
tre). Seventy-one women were not included (37 standard surgery
group, 34 lymphadenectomy group): 39 with no disease and 32
with differentiationnot applicable (histologymixed epithelial stro-
mal sarcoma).
In the trial of Panici 2008, researchers adjusted the HR for age (65
or older, younger than 65 years), tumour grade (grade 1, 2 or 3),
myometrial invasion (50% or more, less than 50%) and tumour
stage (stage I to II, stage III to IV).
A secondary analysis from the Panici 2008 trial assessed survival in
women who underwent lymphadenectomy compared with those
who did not undergo lymphadenectomy in relation to age (older
than 65 years and 65 years or younger).
For distribution of these factors at baseline in each trial by treat-
ment arm, see the Characteristics of included studies table.
The two trials included in the analysis reported adverse events
(direct surgical morbidity, surgery-related systemic morbidity, and
lymphoedema or lymphocyst formation).
Excluded studies
After obtaining the full text, we excluded 41 articles for the fol-
lowing reasons.
• 21 studies were non-RCTs, including retrospective reviews,
in which results were compared between women who underwent
systematic lymphadenectomy and those who did not.
• 11 articles were reviews on the role of lymphadenectomy in
endometrial cancer; none identified any RCT-level evidence.
• 9 studies were RCTs but provided no outcome information
based on randomisation for lymphadenectomy.
For further details on all excluded studies, see the Characteristics
of excluded studies table.
Risk of bias in included studies
The Panici 2008 and Kitchener 2009 trials were at low risk of bias:
They satisfied four of the criteria that we used to assess risk of bias
(see Figure 3 and Figure 4). The Fayallah 2011 trial had an overall
unclear risk of bias, as adequate information was not available
concerning random sequence generation, allocation concealment,
blinding, or completeness of outcome reporting. It was likely that
the Fayallah 2011 study had high risk of attrition bias, as follow-up
of women was limited (see the Characteristics of included studies
table).
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Figure 3. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
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Figure 4. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
The Panici 2008 and Kitchener 2009 trials reported the method
of generation of the sequence of random numbers used to allocate
women to treatment arms and concealment of this allocation se-
quence from participants and healthcare professionals involved in
the trials. Neither trial reported whether outcome assessors were
blinded. It is highly likely that both trials reported all outcomes
that they assessed, but it is not clear whether any other bias may
have been present. At least 95% of women who were enrolledwere
assessed at endpoint in both trials.
Effects of interventions
See: Summary of findings for the main comparison Summary
of findings table
All meta-analyses pooled data from two trials (Kitchener 2009;
Panici 2008).
Meta-analyses of survival were based on HRs that were adjusted
for prognostic variables.
Overall survival
Meta-analysis, assessing 1851 women, showed no differences in
risk of death among women who underwent lymphadenectomy
and those who did not undergo lymphadenectomy, after adjust-
ment for important prognostic factors including age and tumour
grade (HR 1.07, 95% CI 0.81 to 1.43; Analysis 1.1). The percent-
age of variability in effect estimates that was due to heterogeneity
rather than to sampling error (chance) was not important (I2 =
0%). The Panici 2008 study reported no differences in five-year
overall survival among women who underwent lymphadenectomy
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and those who did not undergo lymphadenectomy in relation to
age (HR 1.17, 95% CI 0.56 to 2.46 in those older than 65 years;
HR1.21, 95%CI0.54 to 2.72 in those 65 years of age or younger),
although no adjustment was made for other prognostic factors.
The Fayallah 2011 study also reported no differences in overall
survival between those who underwent pelvic lymphadenectomy
and those who did not.
Recurrence-free survival
Meta-analysis, assessing 1851 women, showed no differences in
risk of disease recurrence between women who underwent lym-
phadenectomy and those who did not undergo lymphadenectomy,
after adjustment for important prognostic factors including age
and tumour grade (HR 1.23, 95% CI 0.96 to 1.58; Analysis 1.2).
The percentage of variability in effect estimates that was due to
heterogeneity rather than to chance was not important (I2 = 0%).
Adverse events
Direct surgical morbidity
Meta-analysis, assessing 1922 women, showed no differences in
risk of direct surgical morbidity between women who underwent
lymphadenectomy and those who did not undergo lymphadenec-
tomy (RR 1.93, 95% CI 0.79 to 4.71; Analysis 2.1). The percent-
age of variability in effect estimates that was due to heterogeneity
rather than to chance may represent moderate heterogeneity (I2 =
50%).
Surgery-related systemic morbidity
Meta-analysis of both trials, assessing 1922 women, showed that
women given lymphadenectomy had higher risk of surgery-related
systemic morbidity than those not given lymphadenectomy (RR
3.72, 95% CI 1.04 to 13.27; Analysis 2.3). The percentage of
variability in effect estimates that was due to heterogeneity rather
than to chance was not important (I2 = 0%).
Lymphoedema or lymphocyst
Meta-analysis, assessing 1922 women, revealed that women given
lymphadenectomyhadhigher risk of lymphoedemaor lymphocyst
formation than those not given lymphadenectomy (RR 8.39, 95%
CI 4.06 to 17.33; Analysis 2.2). The percentage of variability in
effect estimates that was due to heterogeneity rather than to chance
was not important (I2 = 0%).
D I S C U S S I O N
Summary of main results
We found three studies that met our inclusion criteria, but we
were able to include only two of these in the meta-analysis. The
two studies included in the analysis (Kitchener 2009; Panici 2008)
enrolled a total of 1945 women. These studies compared lym-
phadenectomy versus no lymphadenectomy in women with en-
dometrial cancer that was thought on clinical grounds to be con-
fined to the womb.
When we combined the findings from these two studies and ad-
justed for important prognostic factors, we found that risks of
death and disease recurrence were no different among women
who underwent lymphadenectomy than among those who did
not (hazard ratio (HR) 1.07, 95% confidence interval (CI) 0.81
to 1.43; HR 1.23, 95% CI 0.96 to 1.58 for overall and recur-
rence-free survival, respectively). Risk of adverse events was signif-
icantly higher in women who underwent lymphadenectomy (lym-
phoedema and lymphocyst formation; risk ratio (RR) 8.39, 95%
CI 4.06 to 17.33).
The two studies included in themeta-analysis hadmany strengths;
HRs correctly allowed for censoring and provided information
about adverse events. Both studies recruited a substantial number
of women, and investigators observed a reasonably large number of
events in the two survival outcomes and in the number of women
with lymphoedema. Researchers reported no differences in overall
or recurrence-free survival in the two groups of women, but the
risk of adverse events was consistently higher among women who
underwent lymphadenectomy.
Overall completeness and applicability of
evidence
We found no studies that randomly assessed pelvic lymph node
sampling, sentinel lymph node biopsy, pelvic and para-aortic lym-
phadenectomy, or removal of bulky pelvic lymph nodes.
Although we specified quality of life (QOL) as an outcome of
interest, none of the trials reported this. QOL after treatment for
cancer is an extremely important outcome, as treatment-related
morbidity very often degrades the quality of the time that patients
continue to live. This is especially important for a condition that
has relatively good survival rates.
Surgical treatment of endometrial cancer varies among hospitals,
and before the Panici 2008 and Kitchener 2009 studies were pub-
lished, no clear evidence indicated whether lymphadenectomy has
a role in management at early stages of the disease. However, ev-
idence from these RCTs suggests no clear benefit of radical treat-
ment for women with early-stage endometrial cancer.
Additional trials undertaken to assess lymphadenectomy for the
management of endometrial cancer may test the robustness of the
findings of this review, but evidence from two large included tri-
als suggests that the true effect for the primary outcome (overall
survival) may be close to the estimated effect, so it is questionable
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whether additional trials are justified in this area. A higher propor-
tion of women appeared to be disease-free in the lymphadenec-
tomy group compared with the control group, but this finding
was not statistically significant. Meta-analyses in the review found
no differences between lymphadenectomy and standard surgery
in risk of death (HR 1.07, 95% CI 0.81 to 1.43; Analysis 1.1)
or disease recurrence (HR 1.23, 95% CI 0.96 to 1.58; Analysis
1.2), and no differences in direct surgical morbidity (RR 1.93,
95% CI 0.79 to 4.71; Analysis 2.1), but more women experienced
surgery-related systemic morbidity (RR 3.72, 95% CI 1.04 to
13.27; Analysis 2.3) and lymphoedema or lymphocyst (RR 8.39,
95% CI 4.06 to 17.33; Analysis 2.2). According to the Grading
of Recommendations Assessment, Development and Evaluation
(GRADE) approach (GRADE Working Group 2004), the evi-
dence summarised by this review is potentially adequate, and we
are moderately confident in the effect estimates, but they could be
substantially different (especially for recurrence-free survival and
adverse event outcomes).
Quality of the evidence
Overall, the evidence appears to be of moderate quality (GRADE
Working Group 2004) for all outcomes of comparisons of lym-
phadenectomy versus control, with the exception of the presence
or absence of lymphoedema or lymphocyst, which was graded
as high-quality evidence (Summary of findings for the main
comparison). The quality of the evidence for primary outcomes
overall and for recurrence-free survival was moderate and was
mainly downgraded from high-quality evidence because of con-
cerns regarding the degree of uncertainty in the pooled estimates,
as indicated by the 95% confidence intervals and the imprecise
estimates. Two trials (Kitchener 2009; Panici 2008) were at low
overall risk of bias, and one trial (Fayallah 2011) was at unclear
risk of bias but contributed no weight to the meta-analyses and
main findings of this review.
Both of the studies included in themeta-analysis (Kitchener 2009;
Panici 2008) had low risk of bias for concealment of the randomi-
sation sequence from healthcare providers and participants. Inad-
equate concealment of allocation is often associated with overes-
timation of the effects of treatment (Moher 1998; Schulz 1995).
However, blinding of outcome assessors was not reported in either
study. Evidence on overall survival therefore is more robust than
that for recurrence-free survival, as blinding of outcome assessors
is of less relevance for death than for disease progression.
Both trials reported the hazard ratio (HR), which is the best statis-
tic for summarising differences in risk between two treatment
groups over the duration of a trial when time to death or disease
progression is ’censored’ or unknown for some women, as they
were still alive (or disease-free) at the end of the trial.
The two studies provided consistent evidence about all outcomes,
with the exception of direct surgical morbidity, for which the trial
of Kitchener 2009 reported higher risk of direct surgical morbidity
for women who underwent lymphadenectomy than for those who
did not, whereas the trial of Panici 2008 found no differences.
Both studies randomly assignedwomenwhowere thought on clin-
ical evidence to have disease confined to the uterus. However, the
timing of randomisation varied: one was randomly assigned pre-
operatively (Kitchener 2009), and one following examination of
the uterus at the time of surgery (Panici 2008). Another difference
between the two studies was the median number of lymph nodes
removed: 12 (range one to 59) in the Kitchener 2009 study and
26 (range 21 to 35) in the Panici 2008 study. However, despite
this, five-year disease-free survival rates were similar, and a pre-
defined subgroup analysis within Kitchener 2009 found a trend
toward poorer survival when more lymph nodes were removed.
Onemajor difference between the studies was that Kitchener 2009
included low-risk early-stage participants (49% of the standard
surgery group and 42% of the lymphadenectomy group), who
were specifically excluded from Panici 2008, following examina-
tion of the uterus by frozen section intraoperatively. However, a
predefined subgroup analysis within Kitchener 2009 revealed no
evidence of a difference in the relative effect of lymphadenectomy
(P = 0·55 for overall survival; P = 0·35 for recurrence-free sur-
vival) when groups were stratified into low-risk early-stage disease,
intermediate-risk and high-risk early-stage disease, and advanced
disease. From a clinical management perspective, routine use of
whole uterine frozen section is not universally available and is re-
source-intensive; in addition, as the two studies had similar out-
comes in their high-risk groups, this is unlikely to have had amajor
influence on the results.
Both trials permitted removal of suspicious lymphnodes inwomen
allocated to no lymphadenectomy, at the discretion of the surgeon.
Relatively small numbers of women in the control groups of each
study had lymph nodes removed (35 women in Kitchener 2009;
56 women in Panici 2008), and this may cause some difficulty in
interpretation of study results, but it would reflect clinical practice
if lymphadenectomy was not standard treatment in the absence of
suspicious lymph nodes.
Quality of life (QOL) was not reported in any of the trials, so we
could not assess the quality of the evidence, which was very low
for this outcome, but we could not report pertinent adverse events
comprehensively.
We are moderately confident in the effect estimates in all analyses,
but they could be substantially different (especially for recurrence-
free survival and adverse event outcomes).
Potential biases in the review process
We conducted a comprehensive search, including a thorough
search of the grey literature, and three review authors indepen-
dently sifted all studies and extracted data. We restricted included
studies to randomised controlled trials (RCTs), as they provide the
strongest level of evidence available. Hence, we have attempted to
reduce bias in the review process.
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The greatest threat to the validity of the review is likely to be the
possibility of publication bias (i.e. studies that did not find the
treatment to have been effective may not have been published).
We were unable to assess this possibility, as we found only three
included studies. However, as none of the studies reported differ-
ences between lymphadenectomy and no lymphadenectomy, pub-
lication bias seems unlikely.
Agreements and disagreements with other
studies or reviews
A pooled HR for overall survival in the Kitchener 2009 and
Panici 2008 studies was reported as 1.17 (95% CI 0.91 to 1.50)
(Kitchener 2009a), which differs from the findings of this meta-
analysis (HR 1.07, 95%CI 0.81 to 1.43), in which combined data
were adjusted for prognostic factors.
Previous studies and reviews have been based on data from non-
randomised studies. As discussed, some retrospective studies have
demonstrated benefit from pelvic lymphadenectomy (Chan 2006;
Kilgore 1995), whereas other studies have not (Trimble 1998;
Van Lankveld 2006). Similarly, some retrospective studies have
demonstrated benefit from pelvic and para-aortic lymphadenec-
tomy comparedwith pelvic lymphadenectomy alone (Todo 2010),
whilst others have not (Tong 2011).
One retrospective review of 649 women with endometrial cancer
found that women who underwent multiple-site lymph node sam-
pling had improved five-year survival (extrapolated from survival
curves) compared with women who underwent no pelvic node
sampling (five-year survival ~90% vs ~75%; P = 0.002) (Kilgore
1995). However, only disease-specific survival was recorded, non-
endometrial cancer deaths were censored and no details were pro-
vided on participant characteristics, which are known to have
a major influence on endometrial cancer survival (e.g. age, dia-
betes, cardiac comorbidity). Furthermore, retrospective popula-
tion-based studies demonstrated no survival advantage of lym-
phadenectomy (VanLankveld 2006), or showed such an advantage
only for women in high-risk subgroups (high-grade (G3) stage I
disease who did undergo lymph node sampling) (five-year relative
survival for no node sampling 0.83 ± 0.05 (n = 497) versus 0.92
± 0.04 (n = 553) for node sampling; P = 0.0110) (Trimble 1998).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review update does not alter the conclusions of the original
review (May 2010); data do not support routine use of pelvic lym-
phadenectomy in the treatment of endometrial cancer thought to
be confined to the uterus at presentation (presumed stage I dis-
ease). We found no differences in survival between groups, and, in
relation to harmful effects of treatment, women who did not un-
dergo lymphadenectomy showed clear benefit. We found no good
quality data that assessed the role of para-aortic lymphadenectomy,
or removal of grossly enlarged lymph nodes. The two trials that
contributed to the meta-analyses were at low risk of bias, and the
other trial was at unclear risk of bias.
Results demonstrating no benefit of routine lymphadenectomy in
presumed early-stage endometrial cancer are of interest and re-
flect results of RCTs that have examined the role of pelvic ra-
diotherapy in treatment of these women (Kong 2012). In addi-
tion, we found no differences in patterns of recurrence between
pelvic lymphadenectomy groups and standard surgery groups in
the Kitchener 2009 study, which further supports the survival evi-
dence that lymphadenectomy yields prognostic information only,
rather than showing a direct therapeutic benefit. Although prog-
nostic information is useful, these data reveal the real costs to pa-
tients associated with gathering this information and show that
studies that do not look at the long-term sequelae of lymphadenec-
tomy do not allow women to make fully informed decisions about
their health care.
Implications for research
Important questions remain to be answered about the role of lym-
phadenectomy in endometrial cancer. However, neither this meta-
analysis of pelvic lymphadenectomy in early-stage endometrial
cancer nor the Cochrane review on radiotherapy for early-stage
endometrial cancer (Kong 2012) supports routine adjuvant treat-
ment to pelvic nodes for early-stage disease. The overall quality of
the evidence was moderate across all outcomes (high-quality evi-
dence for the presence or absence of lymphoedema or lymphocyst
outcome) and was downgraded because of concerns over impreci-
sion of estimates.
Studies identified in this review examined pelvic lymphadenec-
tomy. We were not able to identify any RCTs that assessed lymph
node sampling or sentinel lymph node sampling, rather than
systematic lymphadenectomy. Likewise, we found no RCTs that
looked at differences between pelvic and para-aortic lymph node
removal. These interventions have been assessed by cohort studies
but have yet to be assessed by RCTs. It is not known whether pelvic
and para-aortic lymph node dissection confers any benefit over
pelvic lymphadenectomy alone, and the benefit demonstrated in
the SEPAL study (Todo 2010) has yet to be replicated by an RCT.
It is important to note that Kitchener 2009 and Panici 2008 data
caution against the assumption that even more surgery will result
in improved survival.
The studies included in this review primarily evaluated the impact
of lymphadenectomy in early-stage disease with low risk of recur-
rence; the role of lymphadenectomy in women with intermedi-
ate and high risk of disease recurrence has yet to be established
by RCTs. Further research is underway to investigate the role of
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imaging technologies in the detection of lymph node metastasis
in endometrial cancer (ISRCTN84527805); findings of this re-
search may aid future researchers in evaluating the impact of lym-
phadenectomy among women with intermediate and high risk of
disease recurrence.
The studies included in this review did not assess use of sentinel
lymph node biopsy, which has the potential to improve staging
whilst minimising surgical morbidity. When lymphadenectomy
or lymph node sampling is not performed, use of adjuvant ther-
apies is based on the pathological findings derived from surgical
specimens. This may lead to inappropriate use, or omission, of
adjuvant therapies. Use of sentinel lymph node biopsy may have
a role in surgical staging. We recommend that data should be as-
sessed by a Cochrane Diagnostic Test Accuracy review to deter-
mine whether the sentinel lymph node approach is valid in en-
dometrial cancer. In addition, future versions of protocols for this
review should include an assessment of the role of sentinel lymph
node biopsy, if this is shown to be adequately sensitive to be used
in an intervention trial.
Studies conducted to determine the role of adjuvant treatment in
early-stage cancer have highlighted that, for most women, sim-
ple surgery alone is sufficient to provide cure. Further research is
needed to allow more individualised treatment strategies, ensur-
ing that women with later-stage or more aggressive cancers receive
appropriate treatment, whilst not exposing women with a good
prognosis to potentially serious lifelong side effects. In addition,
the impact of any intervention on quality of life must be examined
in future studies, particularly for cancer types with good survival
rates.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Fayallah 2011
Methods Single-centre RCT randomly assigning participants from a university hospital in Egypt
Participants 38 women with histologically proven endometrial carcinoma thought to be International
Federation of Gynecology and Obstetrics stage I
Women recruited between April 2005 and October 2008 were randomly assigned pre-
operatively to undergo extra fascial hysterectomy, bilateral salpingo-oophorectomy with
pelvic lymphadenectomy (iliac and obturator lymph nodes) (n = 21) or extrafascial hys-
terectomy and bilateral salpingo-oophorectomy alone (n = 17). Before surgery, immuno-
histochemistry was carried out on endometrial tissue for detection of P53 overexpression.
A total of 30 (79%) women had FIGO surgical stage I disease, four (11%) had stage II
and four (11%) stage III disease. Depth of invasion was as follows: endometrium only 6
(16%); inner half of myometrium 17 (45%); and outer half ofmyometrium or further 15
(39%). Histological cell types were as follows: endometrioid 29 (80%); adenocarcinoma
NOS 4 (11%); and papillary serous 5 (13%). Tumour grade was as follows: 14 (37%)
had tumour grade 1; 16 (42%) grade 2; and 8 (21%) grade 3
No significant difference was noted between arms in terms of age, medical status, surgical
stage, histological type, or grade of tumour. The number of nodes removed from partic-
ipants in either arm was not reported, although the overall number of nodes removed
on each pelvic side was reported as ranging from 6 to 14
After surgery, adjuvant radiotherapy was provided at the discretion of tumour board
members. Women were followed up every 3 months with clinical assessment and ultra-
sound and underwent an MRI every 6 months
Interventions Intervention
Extrafascial hysterectomy with bilateral salpingo-oophorectomy combined with pelvic
lymphadenectomy involving common iliac, external iliac and obturator lymph node
dissection
Comparison
Extrafascial hysterectomy with bilateral salpingo-oophorectomy alone
Outcomes Overall survival
Recurrence rate
Notes Mean duration of follow-up was 21.5 months (range 6 to 40)
Outcomes of overall survival and recurrence ratewere based on the number of participants
known to have died or in whom the disease was known to have progressed, rather than
knowledge of survival and recurrence status among study participants
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
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Fayallah 2011 (Continued)
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk Mean follow-up duration from treatment
was 21.5 months (range 6 to 40 months)
; no other information regarding attrition
was given
Kitchener 2009
Methods Multi-centre RCT randomly assigning participants from 85 centres in 4 countries (UK,
South Africa, Poland, and New Zealand)
Participants 1408 women with histologically proven endometrial carcinoma thought preoperatively
to be confined to the corpus
Median age at the time of randomisation was 63 years (range 36 to 89) for standard
surgery and 63 years (range 34 to 93) for lymphadenectomy
Time from diagnosis to random assignment was≤ 6 weeks for 576 (82%) women in the
standard surgery group vs 588 (84%) in the lymphadenectomy arm and > 6 weeks for
128 (18%) women in the standard surgery group vs 116 (16%) in the lymphadenectomy
arm
1057 participants (75%) had WHO performance status 0; 295 (21%) had status 1; 45
(3%) status 2; 9 (1%) status 3; and 2 (0%) status 4, similarly spread between the 2 groups
650 (92%)womenunderwent open surgery and54 (8%)underwent laparoscopic surgery
in the standard surgery group vs 659 (94%) open and 45 (6%) laparoscopic in the
lymphadenectomy group
Baseline characteristics below excluded participants whose pathology details did not con-
firm endometrial cancer: 39 women (21 standard surgery group, 18 lymphadenectomy
group) who had no other tumour in the surgical specimen; atypical hyperplasia; or cer-
vical, ovarian, or colorectal cancer
Tumour was confined to the corpus uteri in 1091 (80%) women and spread beyond the
corpus in 274 (20%)women: 553 (81%) standard surgery; 538 (79%) lymphadenectomy
Depth of invasion was as follows for standard surgery: endometrium only 96 (14%);
inner half of myometrium 369 (55%); outer half of myometrium 212 (31%): unknown
6 (0.9%) Depth of invasion was as follows for lymphadenectomy: endometrium only
89 (13%); inner half of myometrium 310 (46%); outer half of myometrium 274 (41%)
: unknown 13 (1.9%)
FIGO staging (pre-2009): Stage IIIC was not included, and women with positive lymph
nodes were classified irrespective of nodal status. In the standard surgery group, 553
participants (81%) were stage I according to FIGO, 86 (13%) were stage II and 38 (5.
6%) were stage III or IV. FIGO stage was unknown in 6 (0.9%) participants. In the
lymphadenectomy group, 532 participants (78%) were stage I according to FIGO, 91
(13%) were stage II and 52 (7.5%) were stage III or IV. FIGO stage was unknown in 11
(1.6%) participants
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Kitchener 2009 (Continued)
Histological cell types were as follows for standard surgery vs lymphadenectomy: en-
dometrioid 545 (80%) vs 541 (79%); adenocarcinoma NOS 46 (7%) vs 37 (5%); clear
cell 10 (1%) vs 17 (2%); serous 21 (3%) vs 32 (5%); squamous 6 (1%) vs 5 (1%);
mucinous 1 (< 1%) vs 4 (1%); mixed epithelial stromal 7 (1%) vs 8 (1%); sarcoma 10
(1%) vs 9 (1%); other epithelial 4 (1%) vs 6 (1%); mixed epithelial 31 (5%) vs 25 (4%)
; unknown 2 (0.5%) in both groups
Tumour grade was as follows for standard surgery vs lymphadenectomy: 225 women
(33%) vs 213 (31%) had tumour grade 1; 300 (44%) vs 290 (43%) grade 2; 139 (20%)
vs 158 (23%) grade 3; and in 19 (3%) vs 25 (4%) women, tumour grade was unknown
or was not applicable
Of the 1403 women who completed surgery, surgical technique used in the standard
surgery group was as follows: laparoscopic 42 (6%); vertical incision 287 (45%); Pfan-
nenstiel incision 311 (49%); other transverse 43 (7%); unknown 6. Surgical technique
used in the lymphadenectomy group was as follows: laparoscopic 45 (6%); vertical inci-
sion 384 (60%); Pfannenstiel incision 208 (32%); other transverse 49 (8%); unknown
7. Five women (2 standard surgery; 3 lymphadenectomy) did not undergo completed
surgery
Interventions Intervention
Lymphadenectomy:Women in the lymphadenectomy group had standard surgery plus
a systematic dissection of the iliac and obturator nodes. If the nodes could not be dissected
thoroughly because of obesity or anaesthetic concerns, sampling of suspect nodes was
recommended and para-aortic node sampling was done at the discretion of the surgeon
Comparison
Standard surgery:Women in the standard surgery group had a hysterectomy and BSO,
peritoneal washings and palpation of para-aortic nodes. Nodes that were suspicious could
be sampled if the surgeon believed this to be in the woman’s best interest
Outcomes Overall survival
Recurrence-free survival
Surgical complications
Notes Median duration of follow-up was 37 months (IQR 24 to 58 months)
Specialist gynaecological surgeons who were experienced in pelvic lymphadenectomy
undertook all surgical procedures
69 women in the lymphadenectomy group received a different intervention from the
intervention to which they were assigned: 3 women had no surgery, 2 had subtotal
hysterectomy, 6 women were given unknown intervention and 58 (8%) had no nodes
taken
In the standard surgery group, 2 had no surgery, 6 had subtotal hysterectomy, 11 were
given unknown intervention and 35 (5%) had nodes taken
No adjuvant radiotherapy was received by 471 (67%) in the standard surgery group and
by 469 (67%) in the lymphadenectomy group
Risk of bias
Bias Authors’ judgement Support for judgement
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Kitchener 2009 (Continued)
Random sequence generation (selection
bias)
Low risk “We used amethod of minimisation. Strat-
ification factors were centre, WHO perfor-
mance status (0-1 versus 2 to 4), time since
diagnosis (<= 6weeks versus > 6weeks), and
planned surgical approach (open versus la-
paroscopic)”
Minimisation is a method that attempts to
randomly assignwhile at the same time bal-
ancing groups for several prognostic vari-
ables, so the method of sequence genera-
tion was adequate in this trial
Allocation concealment (selection bias) Low risk “Randomisation was done by a telephone
call to the Medical Research Council Clin-
ical Trials Unit (MRC CTU)”
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk For multivariate Cox model:
% analysed: 1337/1408 (95%)
Selective reporting (reporting bias) Low risk All important survival and adverse event
outcomes have been reported. Survival out-
comes have been analysed using appropri-
ate statistical techniques to account for cen-
soring
Other bias Unclear risk Informationwas insufficient for assessment
of whether an important risk of bias existed
Panici 2008
Methods Multicentre RCT randomly assigning participants from Italy and Chile
Participants Women with preoperative International Federation of Gynecology and Obstetrics stage
I endometrial carcinoma
Median age at time of random assignment was 62 years (IQR 56 to 68): standard surgery
63 (IQR 55 to 68); lymphadenectomy 63 (IQR 56 to 68)
386 participants (75%) were stage I according to FIGO (standard surgery 195 (78%)
; lymphadenectomy 191 (72%)); 43 (8%) were stage II (standard surgery 21 (8%)
; lymphadenectomy 22(8%)); 71 (14%) were stage III (standard surgery 27 (11%);
lymphadenectomy 44 (17%)); and 6 (1%) were stage IV (standard surgery 3 (1%);
lymphadenectomy 3 (1%)). FIGO stage was unknown in 8 (2%) participants (2 in each
group)
Histological cell types were similar between the 2 groups and were as follows: endometri-
oid 474 (92%); adenosquamous 33 (6.4%); clear cell 1 (0%); serous 3 (0.6%); mullerian
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Panici 2008 (Continued)
mixed malignant tumour 2 (0.4); tumour not found 1 (0%)
38 women (7%) had tumour grade 1 (standard surgery 19 (8%); lymphadenectomy 19
(7%)); 298 (58%) grade 2 (standard surgery 148 (59%); lymphadenectomy 150 (57%))
; 169 grade 3 (33%) (standard surgery 78 (31%); lymphadenectomy 91 (35%)); and in 9
(2%) women, tumour grade was unknown (standard surgery 5 (2%); lymphadenectomy
4 (1.5%))
Interventions For both lymphadenectomy and no-lymphadenectomy arms, primary surgery included
standard hysterectomy with bilateral salpingo-oophorectomy
Intervention
Lymphadenectomy group underwent external/common iliac and superficial obturator
node dissection. Systematic/para-aortic lymphadenectomy was performed at surgeon’s
discretion
Comparison
Removal of bulky (> 1 cm) nodes at surgeon’s discretion in no lymphadenectomy arm
Outcomes Overall survival
Disease-free survival (defined as time from random assignment to earliest occurrence of
relapse or death from any cause)
Severe intraoperative complications
Postoperative complications
Notes Median duration of follow-up was 49 months (IQR 27 to 79 months)
38 women in the lymphadenectomy group had fewer than 20 nodes resected
In the standard surgery group, 56 women (22%) underwent lymph node sampling/
removal, and 17 had 20 or more pelvic lymph nodes resected
Para-aortic lymphadenectomy was performed in 69 (26%) of the 264 participants in the
lymphadenectomy group and in 5 (2%) in the standard surgery group
Adjuvant treatment (chemotherapy and radiotherapy) did not vary significantly between
the 2 arms (no adjuvant therapy in 182 (69%) of the lymphadenectomy group and in
162 (65%) of the standard surgery group) (P = 0.07)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were randomly assigned to one
of the two trial arms by a block arrange-
ment that balanced the treatment assign-
ment within each site”
Allocation concealment (selection bias) Low risk “Intraoperative random assignment was
performed centrally by telephone at the
Mario Negri Institute, Milan”
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not reported
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Panici 2008 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk For all outcomes:
% analysed: 514/537 (96%)
By treatment arm:
Intervention: 264/273 (97%)
Comparison: 250/264 (95%)
Selective reporting (reporting bias) Low risk All important survival and adverse event
outcomes have been reported. Survival out-
comes have been analysed using appropri-
ate statistical techniques to account for cen-
soring
Other bias Unclear risk Informationwas insufficient for assessment
of whether an important risk of bias existed
BSO - IQR - interquartile range
FIGO - International Federation of Gynaecology and Obstetrics
MRI - Magnetic resonance imaging
NOS - Not otherwise stated
RCT - Randomised controlled trial
WHO - World Health Organization
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Angoli 2013 Retrospective review; comparison of lymphadenectomy vs no lymphadenectomy; quality of life assessment
Ansari 2013 Systematic review and meta analysis - no additional RCT evidence found
Babilonti 1989 Retrospective review; comparison of lymphadenectomy vs no lymphadenectomy; examination of short-term
complications
Barton 2009 Narrative review article only - no additional RCT evidence found
Bogani 2014 Narrative review article - no additional RCT evidence found
Chan 2006 Retrospective case review
Crosbie 2012 Incorrect comparator - analysis by body mass index only
Fujimoto 2009 Narrative evaluation of RCT only; no primary data
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(Continued)
Gao 2013 Retrospective case review
Havrilesky 2013 Review of study methods only
Hofstetter 2014 Retrospective case review
Huh 2008 All participants underwent lymph node dissection. Study randomly assigned processing of samples
Kang 2009 Retrospective study - no lymphadenectomy randomly assigned
Kim 2012 Systematic review - no additional RCT evidence found
Kitchener 2011 No additional information by relevant comparator
Kitchener 2013 Narrative review article - no additional RCT evidence found
Kyrgiou 2013 Incorrect interventional comparator
Kyrgiou 2013a Incorrect interventional comparator
Lamela 2013 Incorrect interventional comparator
Look 2004 Systematic review - no additional RCT evidence found
Mannel 1989 Retrospective study - no lymphadenectomy randomly assigned
Mariani 2000 Retrospective study
Mosgaard 2013 Incorrect study intervention
Nahhas 1980 Retrospective review of treatment of individuals with stage II endometrial cancer with no randomisation
Obermair 2012 Incorrect study intervention
Poll-Franse 2012 Retrospective non-randomised study assessing health-related quality of life
Puente 2011 Retrospective non-randomised study
Quinn 1993 Randomised controlled trial of progesterone therapy for high-risk endometrial cancer - no surgical randomisation.
Comparison of outcomes of 238 women who underwent pelvic lymphadenectomy vs 774 women who did
not under pelvic lymphadenectomy. Women who underwent lymphadenectomy were younger and showed less
myometrial invasion. Longer overall survival in women with lymphadenectomy. No differences in patterns of
recurrence
Rodolakis 2012 Retrospective non-randomised study
Rossi 2013 Incorrect study design
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(Continued)
Rossi 2014 Incorrect study intervention
Rubin 1990 Retrospective non-randomised study
Salvesen 2001 Systematic review of role of lymphadenectomy in gynaecological malignancies - no RCT or endometrial cancer
found
Schulz 1986 RCT of adjuvant hormonal therapy after surgery for endometrial cancer
Shan 2013 Incorrect study design
Tinelli 2009 Narrative review article - no additional RCT evidence found
Tong 2011 Retrospective case review
Trovik 2013 Incorrect study intervention
Turkler 2013 Retrospective non-randomised study
Watari 2014 Narrative review article - no additional RCT evidence found
Zapico 2013 Incorrect study intervention
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D A T A A N D A N A L Y S E S
Comparison 1. Survival
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall survival 2 1851 Hazard Ratio (Random, 95% CI) 1.07 [0.81, 1.43]
2 Recurrence-free survival 2 1851 Hazard Ratio (Random, 95% CI) 1.23 [0.96, 1.58]
Comparison 2. Adverse events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Direct surgical morbidity 2 1922 Risk Ratio (IV, Random, 95% CI) 1.93 [0.79, 4.71]
2 Lymphoedema or lymphocyst 2 1922 Risk Ratio (IV, Random, 95% CI) 8.39 [4.06, 17.33]
3 Surgery-related systemic
morbidity
2 1922 Risk Ratio (IV, Random, 95% CI) 3.72 [1.04, 13.27]
Analysis 1.1. Comparison 1 Survival, Outcome 1 Overall survival.
Review: Lymphadenectomy for the management of endometrial cancer
Comparison: 1 Survival
Outcome: 1 Overall survival
Study or subgroup Lymphadenectomy
No lym-
phadenec-
tomy log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Kitchener 2009 670 667 0.04 (0.17) 73.1 % 1.04 [ 0.75, 1.45 ]
Panici 2008 264 250 0.15 (0.28) 26.9 % 1.16 [ 0.67, 2.01 ]
Total (95% CI) 934 917 100.0 % 1.07 [ 0.81, 1.43 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours lymphadenectomy Favours no lymphadenectomy
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Analysis 1.2. Comparison 1 Survival, Outcome 2 Recurrence-free survival.
Review: Lymphadenectomy for the management of endometrial cancer
Comparison: 1 Survival
Outcome: 2 Recurrence-free survival
Study or subgroup Lymphadenectomy
No lym-
phadenec-
tomy log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Kitchener 2009 670 667 0.22 (0.15) 71.9 % 1.25 [ 0.93, 1.67 ]
Panici 2008 264 250 0.18 (0.24) 28.1 % 1.20 [ 0.75, 1.92 ]
Total (95% CI) 934 917 100.0 % 1.23 [ 0.96, 1.58 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.64 (P = 0.10)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours lymphadenectomy Favours no lymphadenectomy
Analysis 2.1. Comparison 2 Adverse events, Outcome 1 Direct surgical morbidity.
Review: Lymphadenectomy for the management of endometrial cancer
Comparison: 2 Adverse events
Outcome: 1 Direct surgical morbidity
Study or subgroup Lymphadenectomy
No lym-
phadenec-
tomy Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Kitchener 2009 28/704 10/704 59.8 % 2.80 [ 1.37, 5.72 ]
Panici 2008 7/264 6/250 40.2 % 1.10 [ 0.38, 3.24 ]
Total (95% CI) 968 954 100.0 % 1.93 [ 0.79, 4.71 ]
Total events: 35 (Lymphadenectomy), 16 (No lymphadenectomy)
Heterogeneity: Tau2 = 0.22; Chi2 = 1.99, df = 1 (P = 0.16); I2 =50%
Test for overall effect: Z = 1.44 (P = 0.15)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours lymphadenectomy Favours no lymphadenectomy
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Analysis 2.2. Comparison 2 Adverse events, Outcome 2 Lymphoedema or lymphocyst.
Review: Lymphadenectomy for the management of endometrial cancer
Comparison: 2 Adverse events
Outcome: 2 Lymphoedema or lymphocyst
Study or subgroup Lymphadenectomy
No lym-
phadenec-
tomy Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Kitchener 2009 34/704 4/704 49.5 % 8.50 [ 3.03, 23.83 ]
Panici 2008 35/264 4/250 50.5 % 8.29 [ 2.99, 22.98 ]
Total (95% CI) 968 954 100.0 % 8.39 [ 4.06, 17.33 ]
Total events: 69 (Lymphadenectomy), 8 (No lymphadenectomy)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 5.75 (P < 0.00001)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours lymphadenectomy Favours no lymphadenectomy
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Analysis 2.3. Comparison 2 Adverse events, Outcome 3 Surgery-related systemic morbidity.
Review: Lymphadenectomy for the management of endometrial cancer
Comparison: 2 Adverse events
Outcome: 3 Surgery-related systemic morbidity
Study or subgroup Lymphadenectomy
No lym-
phadenec-
tomy Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Kitchener 2009 6/704 1/704 36.1 % 6.00 [ 0.72, 49.71 ]
Panici 2008 6/264 2/250 63.9 % 2.84 [ 0.58, 13.94 ]
Total (95% CI) 968 954 100.0 % 3.72 [ 1.04, 13.27 ]
Total events: 12 (Lymphadenectomy), 3 (No lymphadenectomy)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.31, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 2.03 (P = 0.043)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours lymphadenectomy Favours no lymphadenectomy
A D D I T I O N A L T A B L E S
Table 1. Pre-2009 FIGO staging
Stage Extent of disease
I Tumour limited to uterine body
IA Limited to endometrium
IB < 1/2 myometrial depth invaded
IC > 1/2 myometrial depth invaded
II Tumour limited to uterine body and cervix
IIA Endocervical invasion only
IIB Invasion into cervical stroma
III Extension to uterine serosa, peritoneal cavity and/or lymph nodes
IIIA Extension to uterine serosa, adnexae or positive peritoneal fluid (ascites or washings)
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Table 1. Pre-2009 FIGO staging (Continued)
IIIB Extension to vagina
IIIC Pelvic or para-aortic lymph nodes involved
IV Extension beyond true pelvis and/or involvement of bladder/bowel mucosa
IVA Extension to adjacent organs
IVB Distant metastases or positive inguinal lymph nodes
Table 2. FIGO staging (2009)
Stage Extent of disease
1 Tumour confined to corpus uteri
IA No or less than half myometrial invasion
IB Invasion equal to or greater than half of the myometrium
II Tumour invasion into cervical stroma but not extending beyond uterus
III Local and/or regional spread of tumour
IIIA Tumour invasion into serosa of corpus uteri and/or adnexae
IIIB Vaginal and/or parametrial involvement
IIIC Metastases to pelvic and/or para-aortic lymph nodes
IIIC1 Positive pelvic nodes
IIIC2 Positive para-aortic lymph nodes with or without positive pelvic lymph
nodes
Stage IV tumour invasion into bladder and/or bowel mucosa, and/or distant metastases
IVA Tumour invasion into bladder and/or bowel mucosa
IVB Distant metastases, including intra-abdominal metastasis and/or inguinal nodes
Pelvic washings/cytology should be recorded separately and now does not change the stage.
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor Lymph Node Excision explode all trees
#2 lymphadenectom*
#3 (lymph NEAR node) NEAR/5 excision*
#4 (lymph NEAR node) NEAR/5 dissection*
#5 (lymph NEAR node) NEAR/5 surg*
#6 (lymph NEAR node) NEAR/5 removal
#7 (lymph NEAR node) NEAR/5 clearance
#8 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7)
#9 MeSH descriptor Endometrial Neoplasms explode all trees
#10 endometr* NEAR/5 neoplas*
#11 endometr* NEAR/5 carcinom*
#12 endometr* NEAR/5 malignan*
#13 endometr* NEAR/5 cancer*
#14 endometr* NEAR/5 tumor*
#15 endometr* NEAR/5 tumour*
#16 (#9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15)
#17 (#8 AND #16)
Appendix 2. MEDLINE search strategy
1 exp Lymph Node Excision/
2 (lymph adj node adj5 (excision* or dissection* or surg* or removal or clearance)).mp.
3 lymphadenectom*.mp.
4 1 or 2 or 3
5 exp Endometrial Neoplasms/
6 (endometr* adj5 (neoplas* or carcinom* or malignan* or cancer* or tumor* or tumour*)).mp.
7 5 or 6
8 randomized controlled trial.pt.
9 controlled clinical trial.pt.
10 randomized.ab.
11 randomly.ab.
12 trial.ab.
13 groups.ab.
14 8 or 9 or 10 or 11 or 12 or 13
15 4 and 7 and 14
Key:
mp=title, original title, abstract, name of substance word, subject heading word, pt=publication type, ab=abstract
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Appendix 3. EMBASE search strategy
1 exp lymphadenectomy/
2 (lymph adj node adj5 (excision* or dissection* or surg* or removal or clearance)).mp.
3 lymphadenectom*.mp.
4 1 or 2 or 3
5 exp endometrium tumor/
6 (endometr* adj5 (neoplas* or carcinom* or malignan* or cancer* or tumor* or tumour*)).mp.
7 5 or 6
8 exp controlled clinical trial/
9 randomized.ab.
10 randomly.ab.
11 trial.ab.
12 groups.ab.
13 8 or 9 or 10 or 11 or 12
14 4 and 7 and 13
Key
mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name, ab=
abstract
Appendix 4. Data abstraction form
Lymphadenectomy for the management of endometrial cancer
Paper ID:
Reviewer:
THE DATA COLLECTION CHECKLIST
April 2009
DATA COLLECTION
Once potentially relevant studies have been identified for a review, the following data should be extracted independently by two
reviewers.
Please record your name and the Study ID (first author and year of publication) in the space provided on this page and on any page(s)
that may be separated from the main checklist (e.g. Results section).
For all items, review authors should mark an X against the appropriate response in each case. In addition, it will be helpful if you cut and
paste relevant supporting text and state its original location in the paper (page/column/paragraph). This facilitates later comparisons
of extracted data. Any other comments can also be recorded in the right-hand side boxes.
Data that are missing or ‘UNCLEAR’ in a published report should be marked clearly on the data collection form.
Items on the data extraction sheet that clearly are not applicable to the study in question should be marked accordingly (i.e. N/A).
After data extraction, review authors should compare their completed data extraction sheets and attempt to reach agreement for each
item on the checklist before submitting their completed data records.
SCOPE OF REVIEW: INCLUSION/EXCLUSION CRITERIA
Inclusion criteria Yes/No/Unclear Relevant supporting text and location (page/column/paragraph)
Were participants adult women diagnosed
with endometrial cancer?
Did the trial include at least 1 of the fol-
lowing comparisons?
• Pelvic lymphadenectomy vs no
lymphadenectomy
• Pelvic lymphadenectomy vs pelvic
41Lymphadenectomy for the management of endometrial cancer (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
lymph node sampling
• Pelvic and para-aortic
lymphadenectomy vs no
lymphadenectomy
• Pelvic and para-aortic
lymphadenectomy vs pelvic
lymphadenectomy
• Removal of bulky pelvic lymph
nodes vs no removal of lymph nodes
Was the type of study design as described
by the authors:
Randomised controlled trial (RCT)
Quasi-randomised controlled trial (quasi-
RCT)
Exclusion criteria
Did the trial not include women with other
concurrent malignancies?
Was the trial not cluster-randomised, or
was it not a cross-over trial?
If any of the inclusion criteria are not satisfied and the an-
swer to any of the questions above is “NO”, the study should
be excluded from the review. COLLECT NO FURTHER
DATA
STUDY DETAILS Relevant supporting text and location (page/column/paragraph)
Country:
If multi-centre, please give details
Please state UNCLEAR if information is
not available
Setting:
Duration:
Indicate N/A as appropriate
Median length of follow-up:
Mean length of follow-up:
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(Continued)
Min length of follow-up:
Max length of follow-up:
Additional information:
Baseline characteristics of participants Relevant supporting text and location (page/col-
umn/paragraph)
Age Mean = Years
SD =
Median = Years
Range:
FIGO stage Number (%) stage I:
Number (%) stage II:
Number (%) stage III:
Number (%) stage IV:
Number (%) unknown:
Grade Number (%) grade I:
Number (%) grade II:
Number (%) grade III:
Number (%) unknown:
Comorbidities
Previous treatment
Additional information
ASSESSMENT OF RISK OF BIAS
Sequence generation
Was the allocation sequence adequately
generated?
Describe in sufficient detail the method
used to generate the allocation sequence to
allow assessment of whether it should pro-
duce comparable groups
Tick one row Relevant supporting text and location (page/column/paragraph)
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(Continued)
Yes e.g. a computer-generated random se-
quence or a table of random numbers
No e.g. non-randomised or quasi-ran-
domised (participants allocated on basis of
date of birth, clinic IDnumber or surname)
Unclear insufficient information about the
sequence generation
ALLOCATION CONCEALMENT
Was the randomisation sequence for al-
locating participants to different arms of
the trial adequately concealed, to prevent
both participants and clinicians provid-
ing treatment from predicting in ad-
vance to which arm of the trial a women
would be assigned?
Yes e.g. when the allocation sequence could
not be foretold
No e.g. allocation sequence could be fore-
told by participants, investigators or treat-
ment providers
Unclear e.g. if use of assignment en-
velopes is described, but it remains unclear
whether envelopes were sequentially num-
bered, opaque and sealed
BLINDING OF OUTCOME ASSES-
SORS
Were the clinicians who assessed disease
progression at the end of follow-up pre-
vented from knowing to which arm of
the trial the women were assigned?
Yes Outcome assessors were blinded
NoNo blinding or incomplete blinding of
outcome assessors
Unclear Information was insufficient to
permit judgement of ‘yes’ or ‘no’
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LOSS TO FOLLOW-UP Enter numbers below Relevant supporting text and location (page/column/para-
graph)
How many participants were enrolled in
each treatment arm?
Intervention
group:
Comparison
group:
Howmany participants were assessed at the
end of follow-up in each treatment arm?
Intervention
group:
Comparison
group:
What% of participants were lost to follow-
up?
Intervention
group:
Comparison group:
Overall:
Nowcode satisfactory level of loss-to-fol-
low-up as Yes/No/Unclear:
Tick one row below
Yes: if fewer than 20% of participants were
lost to follow-up and reasons for loss to fol-
low-up were similar in both treatment arms
No: if more than 20% of participants were
lost to follow-up or reasons for loss to fol-
low-up were different in different treat-
ment arms
Unclear: If loss to follow-up was not re-
ported
Selective reporting of outcomes:
Are reports of the study free of the sug-
gestion of selective outcome reporting?
Yes e.g. if review reports all outcomes spec-
ified in the protocol
No
Unclear
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(Continued)
Other potential threats to validity:
Was the study apparently free of other
problems that could put it at high risk
of bias?
Yes
No
Unclear
CHARACTERISTICS OF THE INTERVENTIONS
Describe the intervention(s) for each study group.
Report this in the words of the paper and give specific details
if they are provided e.g. type of surgeon (gynaeoncologist,
gynaecologist, general surgeon) and experience of surgeon,
etc.
Location of text (page/column/paragraph)
Intervention details:
Comparison details:
Did any women receive a different intervention from the one
to which they were assigned?
Yes/No/Unclear
If the answer to the question above is YES, record any reported
changes in assigned treatment
Intervention:
Comparison:
If women received treatments different from those to which
they were assigned, were outcomes reported in the groups to
which they were assigned?
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(Continued)
Yes/No/Unclear
OUTCOMES
Overall survival
If the followingwere reported, record the
value
Value Relevant supporting text and location (page/column/paragraph)
Unadjusted hazard ratio (HR)
Was the comparison group the reference
group for the estimate of the HR?
Yes/No/Unclear
95% confidence on unadjusted HR
Lower 95% confidence limit
Upper 95% confidence limit
Adjusted hazard ratio (HR)
Was the comparison group the reference
group for the estimate of the HR?
List the factors for which the HR was ad-
justed:
Yes/No/Unclear
95% confidence on adjusted HR
Lower 95% confidence limit
Upper 95% confidence limit
If an HR was reported, record the number
of women in each treatment arm on whom
the estimated HR was based:
Number of women in intervention arm:
Number of women in comparison arm:
If an HR was reported, and if the study was
based on a prespecified protocol for assign-
ing women to intervention group or com-
parison group, was the HR based on an
intention-to-treat (ITT) analysis? i.e. were
women analysed in the groups to which
they were assigned, regardless of which
treatment they received?
Yes/No/Unclear
SE(HR)
SE(ln(HR))
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(Continued)
Var(HR)
Var(ln(HR))
Kaplan-Meier plots Yes/No
Minimum follow-up time
Maximum follow-up time
Log rank P value
Was Cox regression reported? Yes/No
Cox P value
OUTCOMES
Progression-free survival
If the followingwere reported, record the
value
Value Relevant supporting text and location (page/column/paragraph)
Unadjusted hazard ratio (HR)
Was the comparison group the reference
group for the estimate of the HR?
Yes/No/Unclear
95% confidence on unadjusted HR
Lower 95% confidence limit
Upper 95% confidence limit
Adjusted hazard ratio (HR)
Was the comparison group the reference
group for the estimate of the HR?
List the factors for which the HR was ad-
justed:
Yes/No/Unclear
95% confidence on adjusted HR
Lower 95% confidence limit
Upper 95% confidence limit
If an HR was reported, record the number
of women in each treatment arm on whom
the estimated HR was based
Number of women in intervention arm:
Number of women in comparison arm:
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(Continued)
If an HR was reported, and if the study was
based on a prespecified protocol for assign-
ing women to intervention group or com-
parison group, was the HR based on an
intention-to-treat (ITT) analysis? i.e. were
women analysed in the groups to which
they were assigned, regardless of which
treatment they received?
Yes/No/Unclear
SE(HR)
SE(ln(HR))
Var(HR)
Var(ln(HR))
Kaplan-Meier plots Yes/No
Minimum follow-up time
Maximum follow-up time
Log rank P value
Was Cox regression reported? Yes/No
Cox P value
Intervention group Comparison group Location of text (page/column/paragraph)
Total number of women en-
rolled in study
For women enrolled in comparison of intervention/comparison treatment
Number of women enrolled
Number (%) of women who
died
Number of women whose vital
status was known
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(Continued)
Time point at which death was recorded e.g. 1 year/5 years/end of study/not
reported
Median time to death:
Mean (SD) time to death:
Intervention group Comparison group Location of text (page/column/paragraph)
Number (%) of women with
disease progression
Number of women whose dis-
ease was assessed
Time point at which disease progression was recorded e.g. 1 year/5 years/end
of study/not reported
Median time to disease progres-
sion:
Mean (SD) time to disease pro-
gression:
Quality of life outcome
State ‘not reported’ if not given
Response Relevant supporting text and location (page/column/paragraph)
Validated scale Yes/No
Name of scale
Intervention group:
Mean QOL at end of follow-up
SD of QOL at end of follow-up
Number of women assessed for QOL at
end of follow-up
Comparison group:
Mean QOL at end of follow-up
SD of QOL at end of follow-up
Number of women assessed for QOL at
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(Continued)
end of follow-up
Adverse events Number
Intervention group Comparison group Location of text (page/column/paragraph)
Direct surgical morbidity (e.g. injury to bladder, ureter, vascular, small bowel or colon), presence and complications of adhesions,
febrile morbidity, intestinal obstruction, haematoma, local infection)
List below the specific types and numbers of adverse events reported
Surgery-related systemic morbidity (chest infection, thromboembolic events (deep vein thrombosis and pulmonary embolism),
cardiac events (cardiac ischaemias and cardiac failure), cerebrovascular accident
List below the specific types and numbers of adverse events reported
Recovery: delayed discharge, unscheduled re-admission
List below the specific types and numbers of adverse events reported
Lymphoedema and lymphocyst formation
List below the specific types and numbers of adverse events reported
Other side effects not categorised above
List below the severity of bleeding and numbers of adverse events reported
Does the number of adverse events re-
ported above refer to the number of
women who experienced adverse events
or to the number of episodes of adverse
events?
Number of women/Number of episodes
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WH A T ’ S N E W
Last assessed as up-to-date: 30 March 2017.
Date Event Description
2 October 2017 Amended Author contact details amended.
25 September 2017 New search has been performed New search March 2017 - no new studies identified.
25 September 2017 New citation required but conclusions have not
changed
Review revised but conclusions not changed.
H I S T O R Y
Protocol first published: Issue 1, 2009
Review first published: Issue 1, 2010
Date Event Description
29 June 2015 New citation required but conclusions have not changed Review updated
23 June 2015 New search has been performed New study identified. Results unchanged as no data avail-
able to be added to the meta-analysis
C O N T R I B U T I O N S O F A U T H O R S
JF and JM contributed equally to the review update. The protocol was originally developed by JM, KW, HD, and AB. JF, KW, AB,
and JM sifted references, and KW, JF, and AB extracted data, which were checked by JM. AB, JF, and JM co-wrote the results and
conclusions of the review with input from KW.
D E C L A R A T I O N S O F I N T E R E S T
Jonathan Frost - none known
Katie Webster - none known
Jo Morrsion - none known
Andrew Bryant - none known
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S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• Department of Health, UK.
NHS Cochrane Collaboration programme Grant Scheme CPG-506
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In addition to methods described in the protocol, we used the GRADE approach to define the quality of the evidence and the extent
to which we can be confident that an estimate of effect or association is free from bias.
In the most recent update of the review in 2017, as the first step of screening, we applied the machine learning classifier (RCT model)
available in the Cochrane Register of Studies (CRS-web; Wallace 2017). The classifier assigns a probability (from 0 to 100) to each
citation for being a true RCT. For citations that are assigned a probability score of less than 10, the machine learning classifier currently
has a specificity/recall of 99.987% (James Thomas, personal communication). For citations assigned a score from 10 to 100, we screened
them independently and in duplicate using Covidence on-line software (Covidence).
The following methods were specified in the protocol but were not implemented, as we found only three trials that met our inclusion
criteria, only two of which could be included in the meta-analysis. Both trials included in the meta-analysis reported HRs, so we did
not need to estimate RRs. Neither trial reported continuous outcomes such as quality of life and neither included multiple treatment
groups. Both trials were at low risk of bias, so we did not conduct sensitivity analysis around quality. However, the methods specified
below may be required when this review is next updated.
Measures of treatment effect
• If it is not possible to estimate the HR, we will abstract the number of participants in each treatment arm who experienced the
outcome of interest and the number of participants assessed, to estimate a risk ratio (RR).
• For continuous outcomes (QOL measures), we will abstract the final value and the standard deviation of the outcome of interest
in each treatment arm at the end of follow-up for each study, if available.
For dichotomous and continuous data, we will extract the number of participants assessed at endpoint.
Assessment of reporting biases
We will examine funnel plots corresponding to meta-analyses of the primary outcome to assess the potential for small-study effects
such as publication bias. If these plots suggest that treatment effects may not be sampled from a symmetrical distribution, as assumed
by the random-effects model, we will perform further meta-analyses using the fixed-effect model.
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Data synthesis
• For continuous outcomes (e.g. QOL measures), we will pool mean differences between treatment arms at the end of follow-up,
if all trials measured outcomes on the same scale; otherwise we will pool standardised mean differences.
If any trials include multiple treatment groups, we will divide the ‘shared’ comparison group into single treatment groups, and we will
treat comparisons between treatment groups and the split comparison group as independent comparisons.
If possible, we will synthesise studies making different comparisons by using the subgroup methods of Bucher 1997.
Subgroup analysis and investigation of heterogeneity
We will perform subgroup analyses by grouping the trials by:
• early-stage disease low-risk participants (stage IA-B, G1 or G2) versus high-risk participants (stage IB, G3 or stage IC or higher,
any grade); or
• no obvious lymph node enlargement versus lymph node enlargement.
We will consider factors such as age, stage, type of intervention, length of follow-up, and adjusted/unadjusted analysis when interpreting
any heterogeneity.
Sensitivity analysis
We will perform sensitivity analyses that exclude studies at high risk of bias.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Disease-Free Survival; EndometrialNeoplasms [∗ surgery]; LymphNodeExcision [∗adverse effects]; LymphaticMetastasis; Lymphedema
[etiology]; Lymphocele [etiology]; Quality of Life; Randomized Controlled Trials as Topic
MeSH check words
Adult; Female; Humans
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